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ABSTRACT
Background. The presence of tumor cells at the margins of
breast lumpectomy specimens is associated with an increased
risk of ipsilateral tumor recurrence. Twenty to 30 % of
patients undergoing breast-conserving surgery require second
procedures to achieve negative margins. This study evaluated
the adjunctive use of the MarginProbe device (Dune Medical
Devices Ltd, Caesarea, Israel) in providing real-time intra-
operative assessment of lumpectomy margins.
Methods. This multicenter randomized trial enrolled
patients with nonpalpable breast malignancies. The study
evaluated MarginProbe use in addition to standard intra-
operative methods for margin assessment. After specimen
removal and inspection, patients were randomized to
device or control arms. In the device arm, MarginProbe
was used to examine the main lumpectomy specimens and
direct additional excision of positive margins. Intraopera-
tive imaging was used in both arms; no intraoperative
pathology assessment was permitted.
Results. In total, 596 patients were enrolled. False-nega-
tive rates were 24.8 and 66.1 % and false-positive rates
were 53.6 and 16.6 % in the device and control arms,
respectively. All positive margins on positive main speci-
mens were resected in 62 % (101 of 163) of cases in the
device arm, versus 22 % (33 of 147) in the control arm
(p \ 0.001). A total of 19.8 % (59 of 298) of patients in the
device arm underwent a reexcision procedure compared
with 25.8 % (77 of 298) in the control arm (6 % absolute,
23 % relative reduction). The difference in tissue volume
removed was not significant.
Conclusions. Adjunctive use of the MarginProbe device
during breast-conserving surgery improved surgeons’
ability to identify and resect positive lumpectomy margins
in the absence of intraoperative pathology assessment,
reducing the number of patients requiring reexcision.
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MarginProbe may aid performance of breast-conserving
surgery by reducing the burden of reexcision procedures
for patients and the health care system.
Breast-conserving surgery (BCS) has been an estab-
lished approach to surgery for early-stage breast cancer for
more than 30 years.1 Contemporary series report that 60–
75 % of American women with early-stage breast cancer
are treated with BCS.2
BCS for noninvasive and invasive cancer includes a
lumpectomy procedure, with sentinel node biopsy in cases
of invasive disease, and postoperative radiotherapy in most
cases. A successful lumpectomy requires complete removal
of the malignancy, including a margin of surrounding nor-
mal breast tissue. This can be challenging to accomplish
because the microscopic extent of breast cancer can be
difficult for the surgeon to discern. Multiple studies have
demonstrated the association of involved or positive lump-
ectomy margins with an increased risk of ipsilateral breast
tumor recurrence, even in the presence of radiotherapy.3–6
Although there is no universally accepted definition of
negative surgical margins, at least 20 % of patients undergo
more than one procedure to achieve acceptable margins as
part of breast-conserving strategies.2,7,8
The MarginProbe (Dune Medical Devices Ltd, Caesarea,
Israel) was developed to provide surgeons with real-time
intraoperative assessment of lumpectomy margins.
Designed to be used as an adjunct to current surgical
methods, the device measures the local electrical properties
(in the radiofrequency range) of breast tissue. These prop-
erties are dependent on membrane potential, nuclear
morphology, and cellular connectivity and vascularity that
differ between normal and malignant tissue.9 The device’s
sensing diameter is 7 mm, and it provides a positive/nega-
tive reading for each measurement taken. The threshold for a
positive reading was set based on readings directly com-
pared to pathology results.10 The diagnostic performance
was sensitivity 70–100 % and specificity 70–87 %,
depending on the cancer feature size. The performance was
similar for all histology types, including ductal carcinoma-
in situ. In a multicenter trial where patients were randomized
to usual surgical technique versus usual technique with
adjunctive use of the MarginProbe, the rate of reexcision
surgery was reduced by 56 % in the device arm of the trial.11
There was no difference in cosmetic outcomes.
The current study examined the contribution of
adjunctive use of MarginProbe to identification of all
involved lumpectomy margins, reduction in the number of
patients with positive margins at the completion of pri-
mary lumpectomy surgery, and decrease in the necessity
for repeat surgical procedures to achieve acceptable
margins.
METHODS
This study was a prospective, randomized (1:1), double-
arm, controlled trial involving 21 institutions and 53 sur-
geons. Participating centers represented a variety of
practice settings, including academic, community-based,
and private practice sites. Institutional review board
approval was obtained at each site. Inclusion criteria
included patients over 18 years with nonpalpable intra-
ductal and invasive breast cancers. All patients had opted
for BCS. Patients with multicentric or bilateral disease,
those with prior radiotherapy or neoadjuvant chemother-
apy, and those with a history of surgery in the ipsilateral
breast were excluded, as were patients who were pregnant
or lactating.
Informed consent was obtained from all patients.
Patients underwent preoperative localization of their
lesions and removal of main lumpectomy specimens as per
surgeons’ usual practices. All main lumpectomy specimens
were oriented to delineate the six surfaces of the tissue
(superior, inferior, medial, lateral, anterior, and posterior).
After main lumpectomy specimen removal, surgeons used
their usual methods of intraoperative assessment, including
inspection and palpation. Intraoperative pathology assess-
ment was precluded. If a margin was deemed to be positive
or close, additional tissue was excised. Patients were then
randomized to device or control arms (Fig. 1). In the
control arm, surgeons completed the lumpectomies,
including utilizing information from intraoperative imag-
ing, per their routine. In the device arm, the MarginProbe
was additionally used by the surgeon to examine all six
surfaces of the main lumpectomy specimens, with 5–8
measurements per face. A single positive reading identified
a margin as positive. Device output was recorded. Surgeons
were required to excise additional tissue from the corre-
sponding surface of the lumpectomy cavity from every
device-identified positive margin. Additional tissue
removed from the lumpectomy margins was not examined
by the device, nor was the lumpectomy cavity. Because the
device should be used within 20 min after specimen exci-
sion, device arm intraoperative imaging, with additional
excisions if indicated, was performed after device use. In
both study arms, main lumpectomy specimens were inked.
All specimens were evaluated by pathologists who were
blinded to study arm. Tissue dimensions, margin status,
and margin distance for all surfaces were recorded. Spec-
imen volume was calculated based on the Ellipsoid
formula: (p/6) 9 L 9 W 9 D. Subjects were followed
(including additional surgical procedures) until the com-
pletion of surgical treatment. Data were collected until the
earliest of the following events: 2 months after the
patient’s last operation; conversion of the subject to mas-
tectomy; or initiation of chemotherapy. There were no
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restrictions placed on surgeons in terms of the performance
of additional surgical procedures. For the purposes of this
study, a positive margin was considered to be disease
identified at B1 mm from the inked edge of tissue. Diag-
nostic measures, including false-negative and false-positive
rates, were evaluated by comparison of device readings to
pathology gold standard on a margin-by-margin basis.
All statistical analyses were performed by SAS software
(SAS, Cary, NC, USA). Numerical variables were tabu-
lated using mean and standard deviations. Categorical
variables were tabulated using number of observations and
percentages. Statistics were performed at a = 0.05 two-
sided significance level. Rates between arms were com-
pared by Fisher’s exact test. Reexcisions were compared by
Poisson’s regression. No missing data were imputed.
Safety was evaluated by reports of serious adverse
events and adverse events. Safety reports were tabulated by
group, body system, and relation to treatment.
RESULTS
A total of 596 patients were randomized, with 298 in
each arm of the trial. Patient demographics and baseline
characteristics are listed in Table 1. Patients underwent
extensive imaging before surgery. The mean extent of
disease was similar in the two groups. The main specimen
volume was similar in both groups, reflecting no difference
in surgical procedure before randomization.
The disposition of patients in both arms of the trial is
shown in Fig. 2. In similar proportions of patients in both
arms, the main lumpectomy specimen contained at least
one positive margin (Fig. 2, phase I). In patients with
positive margins on initial lumpectomy specimens, an
average of two margins was involved, with no difference
between the two arms. With reference to the patients with
positive main specimen margins, surgeons correctly iden-
tified all positive margins on the main specimen and
removed additional tissue from those involved margins
(Fig. 2, phase II) in 33 of 147 cases (22 %) in the control
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FIG. 1 Lumpectomy procedure





Age, years, mean (SD) 60.3 (11.4) 60.2 (11.1)
Ethnic origin, n (%)
Whitea 250 (83.9) 260 (87.2)
Black 22 (7.4) 17 (5.7)
Asian 12 (4.0) 10 (3.4)
Other 14 (4.7) 11 (3.7)
Body mass index, kg/m2, mean (SD) 27.9 (6.6) 28.6 (6.6)
Diagnosis, n (%)
Invasive ductal 181 (60.7) 202 (67.8)
Invasive lobular 26 (8.7) 13 (4.4)
Mixed invasive 8 (2.7) 5 (1.7)
Ductal carcinoma-in situ 83 (27.9) 78 (26.2)
Receptor status, n (%)
ER positive 251 (84.2) 258 (86.6)
PR positive 223 (74.8) 217 (72.8)
Preoperative imaging, n (%)
Mammogram 296 (99.3) 294 (98.7)
MRI 184 (61.7) 174 (58.4)
Ultrasound 228 (76.5) 289 (97.0)
Preoperative core biopsy, n (%) 287 (96.3) 289 (97.0)
Mean extent of disease, cm 1.7 1.6
Main lumpectomy specimen volume, ml 61 60
SD standard deviation, ER estrogen receptor, PR progesterone
receptor, MRI magnetic resonance imaging
a Including Hispanics
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(p \ 0.0001). Patients for whom positive margins on the
main specimen were not identified remained with positive
final margins after the lumpectomy (Fig. 2, phase III,
branches C1 and D1). Although the main specimen was
cleared, some final margins were persistently positive
because of disease identified at the edge of the additional
tissue resected (phase III, branches C2 and D2) in 8 and 22
cases for the control and device arms, respectively. Inter-
estingly, additional tissue was removed from the
lumpectomy cavity in both arms in cases where the main
specimen was found to have clear margins, resulting in
positive final margins (phase III, branches C3 and D3) in 2
and 8 patients in the control and device arms, respectively.
Table 2 lists the patients’ final margin status after the
primary lumpectomy procedure. In the control arm, 41.6 %
(Fig. 2, branches C1, C2, and C3) of patients had positive
margins compared with 30.9 % (Fig. 2, branches D1, D2,
and D3) of patients in the device arm (p = 0.008), repre-
senting a 26 % reduction in the positive margin rate. Even
though these patients had positive margins, surgeons
determined that certain patients were not candidates for
reexcision because the involved margins were recorded to
be at skin or fascia. Excluding these patients, the significant
difference in candidates for reexcision was maintained,
favoring the device arm (p = 0.013). More patients in the
control arm were candidates for reexcision because of
positive margins originating from the main specimen. In
contrast, there were more candidates for reexcision in the
device arm on the basis of additional cavity shavings
removed.
As shown in Table 2, 19.8 % of patients in the device
arm underwent second procedures for reexcision of
lumpectomy margins compared with 25.8 % of patients in
the control arm, representing a 6 % absolute (23 % rela-
tive) reduction associated with MarginProbe use. The
analysis of this difference also accounted for the small but
statistically insignificant (prerandomization) difference
between arms in the number of main lumpectomy speci-
mens with positive margins (Fig. 2, phase I). With regard
to reexcision procedures that were required because of
positive margins originating from the main lumpectomy
specimens (Fig. 2, branches C1 and D1), the control arm
rate was 20.8 % compared with 10.0 % in the device arm, a
47 % reduction (p = 0.002).
To further evaluate device performance, the volume of
tissue resected was analyzed. Both true-positive and false-
positive device readings resulted in excision of additional
breast tissue. Therefore, total volumes of excision were
calculated across all surgeries (Table 3). As expected, the
volume of tissue in main lumpectomy specimens was
identical in the two arms. In the device arm, there was
more tissue removed in the first surgical procedure, rep-
resenting both true-positive and false-positive margin
excisions. However, there was more tissue removed in
reexcision procedures in the control arm. This led to an
overall difference of 8.5 ml in tissue volume removed
between the two study arms. When normalized to baseline
breast volume, the difference between the arms was 2.6 %.
The performance of the MarginProbe in the provision of
diagnostic information was also evaluated. The margin-
level sensitivity of the device was 75.2 % (95 % CI: 69.4–
81.0), with that of the control arm being 33.9 % (95 % CI:
27.6–40.2). False-negative rates were 24.8 and 66.1 % in
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FIG. 2 Results of intraoperative margin assessment and margin status
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sensitivity in identification of positive margins by the device
came at the expense of a reduction in margin-level specificity:
46.4 % (95 % CI: 42.9–49.9) device versus 83.4 % control
(95 % CI: 81.0–85.8). False-positive rates were 53.6 and
16.6 %, in device and control arms, respectively.
Similar adverse event rates were observed in both
groups: device, 6 events (2 %), and control, 5 events (2 %).
Of these reports, only 1 event was possibly related to the
study device (wound infection).
DISCUSSION
BCS is an established approach to the treatment of early-
stage breast cancer, providing an equivalent outcome with
mastectomy while allowing for preservation of the breast.
An ongoing challenge is the requirement of negative
lumpectomy margins, to reduce the risk for in-breast
recurrence. There is variability in defining acceptable mar-
gin width among surgeons and radiation oncologists.12,13
Although reported reexcision rates vary, it is clear that a
significant proportion of women who undergo BCS require
multiple operations to achieve acceptable margins. Current
techniques for intraoperative assessment have limited effi-
cacy, particularly in cases of nonpalpable and intraductal
disease.14–16 The current trial evaluated a novel device for
intraoperative assessment of lumpectomy margins in a
challenging population with nonpalpable disease. Adjunc-
tive use of the MarginProbe required little additional
operating time (approximately 5 min) and resulted in a
statistically significant improvement in complete identifi-
cation of all positive margins on main lumpectomy
specimens. This study did not test whether the device would
allow for less surgery to be performed if the specimens were
carefully examined intraoperatively by pathologists, with or
without the selective use of frozen section.
However, not all candidates for reexcision underwent
these surgeries during the study period. Although 31 % of
patients in the device arm had at least one positive margin at
the end of the procedure, only 20 % had reexcisions. In the
control arm, 42 % of patients had positive margins, and
26 % underwent reexcisions. Some patients had involved
margins at skin or fascia, which are not amenable to reex-
cision. The design of this study did not constrain surgical
decision making. The decision to perform a reexcision may
be appropriately influenced by many factors, including the
urgency to initiate systemic therapy, the results of genetic
testing, and medical comorbidities. Although reexcision
procedures were collected for 2 months after initial surgery,
these factors may have had some effect on the recorded
rates.
The device was designed with an emphasis on sensitivity
to provide maximal detection of all positive margins. It was
expected that this increase in sensitivity (decrease in false-
negative results) would come at the expense of a reduction in
specificity (increase in false-positive results), as was
TABLE 2 Positive margin status and reexcision lumpectomy procedures





Positive margins after initial surgery
All patients 92/298 (30.9 %) 124/298 (41.6 %) 26 % 0.008
At skin or fascia 15/298 (5.0 %) 18/298 (6.0 %) 0.72
Candidates for reexcision 77/298 (25.8 %) 106/298 (35.9 %) 27 % 0.013
Due to positive margin on main specimens 47/298 (15.8 %) 97/298 (32.9 %) 52 % \0.001
Due to positive margin on shavings 30/298 (10.1 %) 9/298 (3.0 %) \0.001
Reexcision lumpectomy procedures 59/298 (19.8 %) 77/298 (25.8 %) 23 % 0.097; 0.018a
Due to positive margin on main specimens 33/298 (10.0 %) 62/298 (20.8 %) 47 % 0.002
Due to positive margin on shavings 19/298 (7.4 %) 4/298 (1.3 %) 0.002
Due to close margins or other considerations 7/298 (2.3 %) 11/298 (3.7 %) 0.47
a Accounting for the difference between arms in the number of main lumpectomy specimens with positive margins (Fig. 2, phase I)






Main specimen 59.7 61.3 -1.6
Truly positive shavings 6.7 2.7 4
Falsely positive shavings 21 7.7 13
Total tissue removed (initial surgery) 87.5 71.7 15.8
Reexcision surgeries 5.8 12.8 -7
Total for all surgeries 93.3 84.8 8.5
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observed. The cosmetic result after BCS has multiple com-
ponents and may be affected by volume of tissue excised,
tumor location within the breast, size of the primary tumor,
size of the breast, and postoperative radiotherapy. There is
also evidence that reexcision procedures negatively affect
cosmetic outcomes.17 Although cosmesis was not directly
assessed in this study, the only factor potentially affected by
MarginProbe use is volume of tissue excised. Our results
suggest that use of the MarginProbe should have little impact
on the cosmetic result of BCS.
Some studies have demonstrated a significant reduction
in reexcision rates when additional tissue is routinely
removed from all six surfaces of the lumpectomy cav-
ity.18,19 However, a recent report from Massachusetts
General Hospital showed no difference in reexcision rates
in patients undergoing lumpectomy surgery, or lumpec-
tomy plus selected or full-cavity shavings.20 The total
tissue volume removed was smaller in the patients who
underwent select or complete cavity shavings, suggesting
that performance of the main lumpectomy was altered
when removal of additional tissue was anticipated. This
change in surgeons’ approach to the main lumpectomy
specimen has also been reported in other studies.19 At this
point, full-cavity shaving has not been widely adopted.
Achieving acceptable margins at the time of primary
lumpectomy surgery may be increasingly important as
techniques for intraoperative radiotherapy evolve and
ablative approaches to the lumpectomy cavity are
explored.21 When oncoplastic closure techniques are used,
it is especially important to avoid positive margins. Re-
excision procedures may be difficult in these cases because
it can be virtually impossible to accurately identify the
specific margin to be reexcised.22
Use of MarginProbe, as depicted in this study, is not the
complete solution to the complex problem of lumpectomy
margins. This device provides incremental improvement in
reducing reexcision procedures, which is meaningful because
these additional unanticipated procedures burden patients and
the health care system. Although this device adds some
additional cost, it is offset by the cost of reexcision procedures
and costs related to positive margins. More work is needed to
understand the relationship between various margin distances
and in-breast recurrence rates. Additional evaluation of the
new margins of cavity shaving specimens would also provide
important intraoperative information. The use of MarginP-
robe or other technology to interrogate the lumpectomy cavity
might provide additional data regarding the adequacy of
resection. Novel methods for preoperative breast imaging
might also provide a more accurate roadmap for surgical
planning. The number of patients opting for mastectomy
procedures is on the rise. It is possible that the frequent need
for multiple excisions to achieve adequate lumpectomy mar-
gins contributes to this trend.
CONCLUSION
The current study supports the use of the MarginProbe
in lumpectomy surgery in the absence of routine intraop-
erative pathologic assessment. The device provides
surgeons with intraoperative assessment of lumpectomy
margins, allowing directed reexcision of positive margins
and reducing the proportion of patients with positive
margins at the conclusion of surgery. A decrease in reex-
cision procedures can reduce the burden of breast cancer
surgery for the patient and the health care system.
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